Target Practice: Understanding How PARP Inhibitors Take Aim at DDR Mutations Across Solid Tumors

How PARP inhibitors (PARPi) workПодробнее

Developing novel therapeutic strategies to target DNA damage responseПодробнее

PARP-inhibitors: A New Generation of Cancer DrugsПодробнее

PARP InhibitorsПодробнее

What is a PARP Inhibitor? | Dana-Farber Cancer Institute | Science IllustratedПодробнее

Understanding the Biological Targets of PARP InhibitorsПодробнее

TRESR trial: Novel ATR inhibitor, RP-3500, for advanced solid tumorsПодробнее

Assessing cabozantinib with PARP inhibitors in DDR mutant-tumorsПодробнее

Targeted cancer therapy: choosing the right assay to assess PARP inhibitorsПодробнее

Targeting the DNA damage response in gynaecological cancers beyond PARP inhibitors - Dr. Yvette DrewПодробнее

Choosing the correct PARP inhibitor for prostate cancerПодробнее

Optimizing the Use of PARP Inhibitors in Ovarian CancerПодробнее

Mechanisms of PARP Inhibition: A Mode of Targeted Cancer TreatmentПодробнее

Use of PARP1-selective and ATR inhibitors to target DDR signalling pathwayПодробнее

Discussing Targeted Treatment With PARP Inhibitors for BRCA-Mutant Patients Across Tumor TypesПодробнее

Understand the Adverse Events of PARP InhibitorsПодробнее

The Evolution of PARP Inhibitors in Ovarian CancerПодробнее

The Role of Targeting DNA Repair Mutations in Advanced Prostate CancerПодробнее

Predicting cancer patient response to PARP inhibitorsПодробнее